Related Experiment Video
Updated: Sep 17, 2025
07:20
Delivery of Cardioactive Therapeutics in a Porcine Myocardial Infarction Model
Published on: February 10, 2023
1.4K
Tailored therapeutics for cardiomyopathies.
Athanasios Bakalakos1, Emanuele Monda1,2, Perry Mark Elliott3
1Institute of Cardiovascular Science, University College London, London, UK.
Nature Reviews. Cardiology
|June 27, 2025
Summary
Cardiomyopathy, a complex heart muscle disorder, traditionally focuses on symptom management. Emerging therapies aim to target the root genetic causes, offering new hope for patients with these progressive heart conditions.
Area of Science:
- Cardiology
- Genetics
- Molecular Biology
Background:
- Cardiomyopathy encompasses diverse heart muscle disorders with varied causes and mechanisms.
- Current management primarily addresses symptoms and prevents complications like heart failure, with limited success in treating progressive dysfunction.
- Few etiology-targeted therapies exist in cardiology, making cardiomyopathies a prime area for therapeutic innovation.
Purpose of the Study:
- To review promising therapeutic approaches for cardiomyopathy.
- To discuss novel strategies targeting the underlying causes of heart muscle disorders.
- To explore the potential impact of these innovative therapies on patients and their families.
Main Methods:
- Review of current literature on cardiomyopathy pathogenesis and treatment.
- Analysis of emerging pharmacological and genetic therapies.
- Discussion of cellular and molecular pathways involved in disease progression.
Main Results:
- Identification of several promising therapeutic strategies for cardiomyopathy.
- Highlighting the potential for therapies to address the disease at its source by targeting genetic causes.
- Exploration of novel or repurposed pharmacological agents and genetic variant modification.
Conclusions:
- Cardiomyopathies present a unique opportunity for developing targeted therapies due to their often monogenic origins.
- Advances in understanding molecular pathways are paving the way for innovative treatments.
- New therapeutic approaches hold promise for significantly improving patient outcomes and quality of life.
Related Concept Videos
01:29Cardiomyopathy V: Interprofessional Care
40
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
40
01:30Cardiomyopathy II: Dilated Cardiomyopathy
30
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
30
01:26Heart Failure Drugs: Inotropic Agents
743
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
743
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
64
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
64
01:14Myocarditis III: Medical Management
18
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
18
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy
42
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
42